# Open-label Multicenter Study to Evaluate the Efficacy of PLX-PAD for the Treatment of COVID-19

> **NCT04614025** · PHASE2 · TERMINATED · sponsor: **Pluristem Ltd.** · enrollment: 23 (actual)

## Conditions studied

- COVID
- ARDS

## Interventions

- **BIOLOGICAL:** PLX-PAD

## Key facts

- **NCT ID:** NCT04614025
- **Lead sponsor:** Pluristem Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-10-19
- **Primary completion:** 2021-08-04
- **Final completion:** 2023-02-07
- **Target enrollment:** 23 (ACTUAL)
- **Why stopped:** The decision to bring the Study to early clinical readout came in response to COVID-19's evolution as a disease, and the significant changes in the standard of care, leading to an increase in the severity of conditions of the intubated patients.
- **Last updated:** 2024-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04614025

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04614025, "Open-label Multicenter Study to Evaluate the Efficacy of PLX-PAD for the Treatment of COVID-19". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04614025. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*